S84 Stock Overview
A biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Scope Fluidics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł34.10 |
| 52 Week High | zł51.60 |
| 52 Week Low | zł31.10 |
| Beta | -0.21 |
| 11 Month Change | -3.94% |
| 3 Month Change | -1.16% |
| 1 Year Change | 9.65% |
| 33 Year Change | 34.78% |
| 5 Year Change | n/a |
| Change since IPO | 12.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| S84 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.9% | 3.6% | 1.5% |
| 1Y | 9.6% | 3.6% | 12.6% |
Return vs Industry: S84 exceeded the German Medical Equipment industry which returned 3.6% over the past year.
Return vs Market: S84 underperformed the German Market which returned 12.6% over the past year.
Price Volatility
| S84 volatility | |
|---|---|
| S84 Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: S84 has not had significant price volatility in the past 3 months.
Volatility Over Time: S84's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 40 | Piotr Garstecki | www.scopefluidics.com |
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.
Scope Fluidics S.A. Fundamentals Summary
| S84 fundamental statistics | |
|---|---|
| Market cap | €103.25m |
| Earnings (TTM) | -€5.28m |
| Revenue (TTM) | €21.74k |
4,748x
P/S Ratio-19.5x
P/E RatioIs S84 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S84 income statement (TTM) | |
|---|---|
| Revenue | zł93.00k |
| Cost of Revenue | zł1.97m |
| Gross Profit | -zł1.88m |
| Other Expenses | zł20.72m |
| Earnings | -zł22.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -8.29 |
| Gross Margin | -2,022.58% |
| Net Profit Margin | -24,304.30% |
| Debt/Equity Ratio | 0% |
How did S84 perform over the long term?
See historical performance and comparison